Cameron Sepahi

325 posts

Cameron Sepahi banner
Cameron Sepahi

Cameron Sepahi

@CameronSepahi

Tweets are NFA and my opinions only. Do your own research!

Bergabung Ocak 2018
281 Mengikuti143 Pengikut
Tweet Disematkan
Cameron Sepahi
Cameron Sepahi@CameronSepahi·
People make the mistake in analogizing Ethereum to operating systems. Instead, it should be analogized to protocols, like TCP/IP.
English
3
0
9
0
Cameron Sepahi
Cameron Sepahi@CameronSepahi·
Thesis on $HAIR @anagenxyz Hair DAO is what happens when you take the compounding pharmacy model, strip out the middlemen, and rebuild it on-chain for hair loss medicine. No insurance gatekeeping. No 2028 launch dates. A community of patients and researchers co-owning the drugs from day one. So what is it actually? A token-governed biotech company targeting the $30B+ hair loss category. Two molecules define this entire space: minoxidil and dutasteride. Anagen has reformulated both and is shipping them now through a real US compounding pharmacy. The business model in plain English Real pharmacy revenue flowing back to the DAO. $HAIR holders own the IP, the pipeline, and the upside. No specialty insurance fight, no patent wall protecting a VC’s markup until 2043. Priced for normal people from day one. Proof of product Two launches in two weeks. Not a whitepaper. Not a roadmap. Actual drugs, available now, in all 50 states. MINX is the extended release oral minoxidil. Same thesis Wall Street paid $256M to validate when Veradermics IPO’d on the NYSE and more than doubled on day one. Except MINX is live now, not 2028. The dissolution data just dropped and it shows exactly what you want to see: standard oral minoxidil spikes and crashes, the MINX lipid matrix releases slowly and steadily across hours at intestinal pH. That’s the formulation difference that actually matters for tolerability and consistency. Maxx is the 10x strength dutasteride built on the same precision delivery vehicle. The drug that works on the patients finasteride couldn’t save, finally delivered without flooding the rest of your body with it. The pipeline angle Big pharma turns reformulations like these into multi-year projects and price hikes. Anagen shipped both like software updates and didn’t raise the price to match. That velocity is structural not accidental. When you own the pharmacy, the doctors, and the IP, you move differently. The structural reality Veradermics raised $256M for one product that doesn’t ship until 2028. $HAIR holders own a real pharmacy shipping better versions of both molecules right now. Two drugs, two of the most validated molecules in the entire hair loss category, both live, both accessible, both owned by the DAO. Things to watch MINX and Maxx user growth and retention data as the launches mature. Additional pipeline reformulations from Anagen. Revenue disclosures back to the DAO. Any pharma or licensing interest in the delivery IP, because that’s where the real repricing event comes from. TLDR: A DAO that owns a real compounding pharmacy, ships better versions of the two defining molecules in hair loss medicine, and just published dissolution data proving the formulation works, while most of the market still thinks DeSci is just whitepapers. Not financial advice. Do your own research. $HAIR
Cameron Sepahi tweet media
English
0
2
3
85
Cameron Sepahi
Cameron Sepahi@CameronSepahi·
@anagenxyz And they said they weren’t using AI/agents. Just wait until they find out..
English
0
0
0
5
Cameron Sepahi me-retweet
Anagen💈
Anagen💈@anagenxyz·
We're training a machine learning model to automatically identify every compartment of the human hair follicle. Over 2,000 stained sections. The goal is to automate analysis that currently takes researchers hours per slide. Stay tuned.
Anagen💈 tweet media
English
1
5
19
991
Cameron Sepahi
Cameron Sepahi@CameronSepahi·
@TrustlessState It’s just tracking M2 + GDP growth. Tech indices are higher beta but have more exposure to GDP growth (i.e. AI / AI infrastructure spend accounts for 75% of GDP growth right now).
English
0
0
2
190
Cameron Sepahi
Cameron Sepahi@CameronSepahi·
The math resolves when you factor in what Fortune 500 companies are actually spending on API access, not individual devs, not Max subscribers. A single enterprise contract can dwarf thousands of individual accounts. Feels like the fundamental question is what % of your margins are you willing to erode for every dollar of efficiency you think you’re gaining?
English
0
0
1
152
Chamath Palihapitiya
Well, one fucked up and non obvious part of the answer could be that certain folks are paying massive amounts to them to distill the model via API. But the revenue is so worthwhile that they could stop it but instead allow it because it allows them to stay ahead in the funding race by showing evermore increasing revenue. Aka my enemy’s enemy is my friend.
Doug Colkitt@0xdoug

I’m really struggling to see how the back of the envelope math on this works out… There are generously 4 million characterized “software workers” in America. That’s pretty broad and includes a lot of people who aren’t really classical engineers don’t produce that much code. That comes out to nearly $1k per month of average Claude spend across every dev in America. Yes, there’s some international usage, but it can’t be that much. Yes there is some non software Cowork usage, but that doesn’t use that many tokens. Yes, some non engineers are using Claude to vibe code, but I really doubt many are spending hundreds per month on. Even if we assume 50% of all software workers are using Claude, that comes out to $2k spend per month per Claude user. Thats 10X more than the highest tier Max subscription. So almost all of Anthropics revenue has to be API billing So the only explanation is that something like 20%+ of software engineers are not only Claude users but on API billing and regularly spending thousands per month. At $5/m Opus tokens that means the average API user has to be going through something like 25 million tokens per day. *OR* the other possibility is API revenue is heavily power law dominated. Maybe there’s just something like 100k super users who are making up the majority of the revenue. For that to work the typical super user would have to be spending on the order of $50k/month and guzzling nearly 1 billion tokens per day.

English
40
5
250
127.1K
TheS◎Lstice
TheS◎Lstice@The__Solstice·
Biotech is the next ai
English
66
12
140
10.4K
Cameron Sepahi
Cameron Sepahi@CameronSepahi·
MINX is solving the exact opposite problem. Instead of delivering more drug systemically, it’s engineered for controlled, sustained release — the dissolution data shows gradual absorption over hours at intestinal pH. That’s the formulation breakthrough that actually matters for long-term tolerability and consistency. Extended release done right isn’t about potency. It’s about precision. MINX is built on that principle from the ground up, manufactured through a real US compounding pharmacy, available now, and priced for normal people. The thesis Wall Street paid $256M to validate is already here. $HAIR
Anagen💈@anagenxyz

Introducing Maxx Precision Dutasteride We increased the concentration by 10x. Same specialized delivery vehicle with added strength. Available online in all 50 states. Claim yours: anagen.xyz/products/maxx-…

English
0
1
4
108
Ana Mostarac
Ana Mostarac@anammostarac·
The “turbocharged” drug is essentially a much more potent form of oral Minoxidil, delivering “twice the amount of the drug over 12 hours compared to the standard version.” If you’re familiar with the side effects of oral Minoxidil currently on the market, you’ll know this is a very, very bad idea.
Ana Mostarac tweet media
English
14
2
65
14.1K
Cameron Sepahi me-retweet
Cameron Sepahi
Cameron Sepahi@CameronSepahi·
Why Anagen ($HAIR) might be the realest thing in DeSci right now — and why MINX is the moment it clicks. 1/ Most DeSci is vibes and whitepapers. "The science is coming." "Wait til next cycle." Anagen (formerly HairDAO) isn't that. It's a growing IP portfolio, live telehealth revenue, a real pipeline, and a DAO that actually ships products. The thing you were promised DeSci would be — it's already here, just quietly. 2/ Quick token breakdown since people keep asking: $HAIR is governance + treasury + revenue rights over the IP portfolio and Anagen telehealth. Everyone holds the same token — team, community, VCs. No secret equity pool. No dual-class nonsense. $HAIR is $HAIR. $LAB is the utility token. Discounts on Anagen products, access to proprietary lab data and experiment feeds. It has zero governance rights, zero treasury claim, zero revenue share — so it literally cannot dilute $HAIR. Different jobs, different tokens. 3/ The market is simple. Hair loss is massive, global, and dominated by two drugs (finasteride, minoxidil) that are decades old and work for some people some of the time. Somebody is going to build the next generation. The only question is whether it happens inside pharma or around it. 4/ Which is where MINX comes in. 👇 5/ Context: in February, Veradermics IPO'd on NYSE under "MANE." Stock more than doubled on day one, closing at $37.75 against a $17 offer price. $256M raised. The entire pitch is an extended-release oral minoxidil tablet called VDPHL01. Wall Street just wrote a $256M check to say "yes, extended-release oral minoxidil is the future of hair loss." 6/ Here's the part that's funny: minoxidil itself is off-patent. Decades old. Nothing proprietary about the molecule. Veradermics' moat is the delivery system. Which means once the category is validated — and it just very publicly was — the door is open for other formulations to walk right through it. 7/ MINX is Anagen's version. Lipid-matrix oral minoxidil, 5mg, designed for prolonged release and steadier plasma exposure. Same category the public markets just paid a premium for. Launching soon, not the back half of this decade. 8/ Why does extended release even matter? Regular oral minoxidil peaks within about an hour and has a plasma half-life around 4.2 hours. That PK curve was designed for lowering blood pressure in the 80s, not growing hair. Flatten the curve and you get lower peaks (safer on the heart), longer time above the hair-growth threshold, and potentially better sulfation at the follicle — which is where minoxidil actually turns into the thing that works. It's a better shape for the job. 9/ Meanwhile, VDPHL01's Phase 3 readouts are still rolling out (Study 302 topline in H1 2026, Study 304 in H2 2026), FDA approval is 2028-2029 at the earliest, and when it launches it'll carry specialty branded pricing (patent runs to 2043, so... use your imagination). MINX is weeks away. US pharmacy. Board-certified docs. Priced like a product people can actually afford. 10/ This is the whole Anagen playbook in one launch: Find what works → formulate it better → ship it fast → price it fairly → let token holders share the upside. No 5-year FDA runway required. No IPO roadshow. Just a DAO that happens to own patents, a pharmacy partner, and doctors. 11/ First batch of MINX is limited. Waitlist is open at anagen.xyz. If you've been waiting for DeSci to produce something real — in a category the public markets just loudly validated — this is the one to pay attention to. 12/ Disclosure: I hold $HAIR. Bought more this week. Market is what it is, but I've never been more convinced about the fundamentals. Not financial advice. Do your own work. But do the work.
English
2
3
16
3.7K
Cameron Sepahi
Cameron Sepahi@CameronSepahi·
They just showed the dissolution curve live. Standard oral minoxidil: spikes and crashes. MINX lipid matrix: smooth, sustained release for hours. This is what “extended release” actually looks like when it works. Not a marketing slide, but a pharmacokinetics graph. Hair loss treatment is finally getting interesting. $HAIR
Anagen💈@anagenxyz

MINX dissolution data is in. Standard oral minoxidil: basically dumps immediately. MINX 5mg lipid matrix: slow, gradual release for hours -- especially at intestinal pH. We’re going live on @Pumpfun to walk through the data. This is where hair loss drug development gets fun.

English
0
6
13
950
Cameron Sepahi me-retweet
🧬DeCurious.bio/acc
🧬DeCurious.bio/acc@YDecurious·
$LAB should be the no 1 token on this list 👀 @desciatoms. Aren't you tracking it?? And @dexscreener why is $LAB not on trending tokens list as well? 😕
DeSci Atoms@desciatoms

⚛️DeSci Atoms Market Update 2 May 2026 MarketCap 24hrs Top Gainers 1. VENOM ($VENOM) +68.84% @BlueScorpionUSA 2. TROL ($TROL) +65.26% 3. BioLLM ($BioLLM) +40.92% @Bio_LLM Overall DeSci Atoms Marketcap Total Market Cap: $441,698,270.77 +0.66% Total 24hrs Volume: $1,880,007.01 -54.69%

English
1
2
6
313
Cameron Sepahi
Cameron Sepahi@CameronSepahi·
@AndrewSteinwold Doesn’t need to innovate to add productivity. Reducing human redundancy is 90% of the equation (so far).
English
0
0
0
38
Andrew Steinwold
Andrew Steinwold@AndrewSteinwold·
Is AI actually helping us solve problems, or are we just addicted to the slot-machine dopamine hit of the prompt box?
English
194
20
547
57.1K
Cameron Sepahi me-retweet
Cheffa
Cheffa@0xCheffa·
$LAB + HairDAO (now powering @anagenxyz) = The Real DeSci Play Actually Shipping Hair Loss Cures Hair loss sucks. Pharma ignored it for decades because it’s “cosmetic.” HairDAO said screw that — and built a fully verticalized, patient-owned pharma stack using decentralized science. Here’s what they’re actually doing right now: • 7 patents filed + 1 live decentralized trial running on real patients • Their own wet lab + tissue bank in NYC doing high-throughput human hair follicle testing • Open-source R&D where patients log results, vote on projects, and earn tokens • Real products shipping today via Anagen telehealth (available in all 50 states): proprietary peptides, treatments, and just dropped Maxx Precision Dutasteride (10x concentration upgrade with specialized delivery) $HAIR is the governance king — controls the treasury, IP portfolio, and DAO decisions. $LAB (on Solana) is the lab token that expands everything without diluting $HAIR. It’s the infrastructure layer turning raw science into scalable peptides and regulated U.S. distribution. Real utility. Real products. No fluff. This isn’t another meme promising a cure. This is a community that: • Cut R&D costs dramatically • Patented novel ideas • Launched consumer products straight from the lab • Built the rails for nationwide access Millions suffer from hair loss. HairDAO is the first group treating it like the serious problem it is — with transparency, speed, and skin in the game. $LAB is still flying under the radar while the ecosystem cooks. If you want exposure to actual biotech progress in crypto (not just hype), this is it. DYOR, but the lab is open and the products are live → anagen.xyz $HAIR 🥇 $LAB 🥈
English
1
7
18
1.3K
Cameron Sepahi me-retweet
Anagen💈
Anagen💈@anagenxyz·
@DiamondNetx @Pumpfun 1) discount on anagen.xyz products 2) first access to lab data 3) potential buy back & buy with anagen profits if the token MC crosses $100 mn (inflation adjusted)
English
1
1
9
676
Cameron Sepahi
Cameron Sepahi@CameronSepahi·
@anagenxyz @andrew_bakst @Pumpfun This is the future of hair loss drug discovery and execution. With line of sight to solve other underfunded bio research that pharma incumbents won’t touch. And $HAIR trades at an ~$11M market cap.
English
0
0
6
170
Cameron Sepahi me-retweet
Anagen💈
Anagen💈@anagenxyz·
MINX dissolution data is in. Standard oral minoxidil: basically dumps immediately. MINX 5mg lipid matrix: slow, gradual release for hours -- especially at intestinal pH. We’re going live on @Pumpfun to walk through the data. This is where hair loss drug development gets fun.
English
6
7
32
5.2K
Cameron Sepahi me-retweet
Anagen💈
Anagen💈@anagenxyz·
@BioProtocol Maxx Precision Dutasteride launches today MINX in 10 days Get ready for the biggest product drops in DeSci anagen.xyz
English
0
1
7
119
Cameron Sepahi me-retweet
🧬DeCurious.bio/acc
🧬DeCurious.bio/acc@YDecurious·
Don't forget to Buy $HAIR, and stake on the Bio lauchpad to accumulate XP so you get to participate in the next ignition sales. gHair gBio Lock in 🔒🚀
English
1
1
4
171